A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

BACKGROUND: Patients with DLBCL who are ineligible for or have relapsed after aggressive salvage chemotherapy have a poor prognosis. CD40 is expressed on multiple B-cell neoplasms including DLBCL and is a potential target for immunotherapy. Dacetuzumab (SGN-40), a non-blocking, partial agonist, huma...

Descripción completa

Detalles Bibliográficos
Autores principales: de Vos, Sven, Forero-Torres, Andres, Ansell, Stephen M, Kahl, Brad, Cheson, Bruce D, Bartlett, Nancy L, Furman, Richard R, Winter, Jane N, Kaplan, Henry, Timmerman, John, Whiting, Nancy C, Drachman, Jonathan G, Advani, Ranjana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065310/
https://www.ncbi.nlm.nih.gov/pubmed/24919462
http://dx.doi.org/10.1186/1756-8722-7-44

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065310/
https://www.ncbi.nlm.nih.gov/pubmed/24919462
http://dx.doi.org/10.1186/1756-8722-7-44

Ejemplares similares